Loading clinical trials...
Loading clinical trials...
Adherence to Otezla in Patients With Mild Psoriasis
Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.
Psoriasis patients prefer oral treatments and are more adherent to orals than to topicals, but adherence to oral treatment of psoriasis may still be limited, compromising treatment outcomes. How well the medication works in the patients who take treatment regularly is not well characterized.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Start Date
June 1, 2025
Primary Completion Date
November 1, 2025
Completion Date
February 1, 2026
Last Updated
May 29, 2025
Otezla - Standard Care
DRUG
Reminder Text Intervention with apremilast
BEHAVIORAL
Extended Consultation for apremilast
BEHAVIORAL
Lead Sponsor
Wake Forest University Health Sciences
Collaborators
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions